October 4, 2013
The Japan Pharmaceutical Manufacturers Association (JPMA) decided on October 3 to suspend Novartis Pharma’s membership for an indefinite period in response to problems with clinical studies of the company’s angiotensin receptor blocker (ARB) Diovan (valsartan). The decision was made by...read more